Evolus, Inc. (NASDAQ:EOLS) CFO Sells $17,208.10 in Stock

Evolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 1,586 shares of the firm's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.85, for a total value of $17,208.10. Following the completion of the transaction, the chief financial officer now owns 146,916 shares in the company, valued at approximately $1,594,038.60. This trade represents a 1.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Evolus Stock Up 4.6 %

EOLS traded up $0.50 during trading hours on Thursday, reaching $11.35. 541,978 shares of the stock traded hands, compared to its average volume of 588,928. Evolus, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $17.82. The company has a market cap of $718.69 million, a price-to-earnings ratio of -12.47 and a beta of 1.27. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The firm's fifty day simple moving average is $13.56 and its two-hundred day simple moving average is $13.75.

Institutional Trading of Evolus

Several large investors have recently modified their holdings of the business. Essex Investment Management Co. LLC boosted its holdings in Evolus by 0.4% in the third quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company's stock valued at $4,788,000 after purchasing an additional 1,111 shares during the last quarter. Arizona State Retirement System raised its position in shares of Evolus by 9.4% in the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company's stock valued at $158,000 after purchasing an additional 1,253 shares in the last quarter. Creative Planning boosted its stake in shares of Evolus by 23.7% during the 3rd quarter. Creative Planning now owns 15,451 shares of the company's stock valued at $250,000 after buying an additional 2,963 shares during the last quarter. Sei Investments Co. grew its position in shares of Evolus by 9.8% during the second quarter. Sei Investments Co. now owns 33,802 shares of the company's stock worth $367,000 after buying an additional 3,020 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of Evolus in the second quarter worth $43,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Evolus in a research report on Monday, September 16th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of Evolus in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. Finally, Barclays increased their target price on Evolus from $16.00 to $20.00 and gave the company an "overweight" rating in a research note on Friday, September 13th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.